NANOBODIES MARKET ANALYSIS

Nanobodies Market, By Product Type (Monovalent Nanobodies, Bivalent Nanobodies, Bispecific Nanobodies, Biparatopic Nanobodies, Multivalent Nanobodies, Fusion Nanobodies), By Therapeutic Area (Oncology, Infectious Diseases, Inflammatory and Autoimmune Diseases, Neurological Disorders, Others), By Application (Therapeutic, Diagnostic, Research), By End User (Hospitals, Biopharmaceutical Companies, Diagnostic Laboratories, Others), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Published In : Sep 2023
Code : CMI1680
Pages :175
Formats :
Excel and PDF
Industry : Biotechnology

Market Challenges And Opportunities

Limitations associated with nanobodies

Global Nanobodies Market- Cross Sectional Analysis:

In the North America region, the product type segment is expected to be dominant as the key players are focused on getting approvals from regulatory authorities, which is also expected to boost the nanobodies market in the North America region. For instance, in February 2021, Sanofi received approval from the U.S. Food and Drug Administration for Cablivi (caplacizumab-yhdp) to treat adults with acquired thrombotic thrombocytopenic purpura (aTTP). The Cablivi provides an effective treatment option for people suffering from thrombotic thrombocytopenic purpura (aTTP).

Global Nanobodies Market: Restraint

Limitations associated with nanobodies: Nanobodies are increasingly used in research, diagnostics, and cancer therapeutics. However, the limitations of nanobodies are likely to hamper the global nanobodies market’s growth. For instance, in February 2021, according to AZoLifeSciences.com, a platform designed to share life science news and stories, nanobodies have significant limitations and disadvantages that limit the use of nanobody. For example, the heavy-chain antibodies from which nanobodies are developed can only be obtained from camelids and sharks. Traditional monoclonal antibodies like infliximab and adalimumab, on the other hand, are obtained from mice. Therefore, the development of nanobodies requires larger, more complicated housing and animal husbandry for obtaining the desired antibody. Key players are focusing on developing advanced products with limited disadvantages, which is expected to drive market growth over the forecast period.
Counterbalances: It would allow the creation of novel antibodies to be made more easily by means of methods for designing antibodies, even if they do not involve a larger scale of animal husbandry.